Back to Results

Ernexa Therapeutics Inc (ERNA)

Ernexa Therapeutics Inc. is a biotechnology company focused on preclinical development of induced mesenchymal stem cell (iMSC) therapies for serious diseases. Its research program targets solid tumors and autoimmune disorders, with lead candidates including ERNA-101, an allogeneic iMSC designed to secrete pro-inflammatory cytokines for ovarian cancer, and ERNA-102, an iMSC engineered to secrete the anti-inflammatory cytokine IL-10 for rheumatoid arthritis. The company has a license agreement with Factor Bioscience Limited. Founded in 2018 and based in Cambridge, Massachusetts, the company adopted the Ernexa Therapeutics name in March 2025 after previously operating as Eterna Therapeutics Inc.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-ERNA
$4.43
16.5% Upside
Fair
$30
689.5% Upside
Bargain
Weak
0.0%
November 11, 2026
1.9x
6.203 M
1.525 M
5.1%
73.7%
-60.9
72.3%
Valuation • Fair Value

Ernexa Therapeutics Inc (NASDAQ-ERNA) Fair Value by Valuation Model

Review the available estimates for Ernexa Therapeutics Inc (NASDAQ-ERNA), including Comps Fair Value.

Primary Valuation Read

Fair Value

$4.43

Estimated upside of 16.5% versus the current market price.

Fair Value Confidence

Very low

Confidence level for the primary fair value estimate.

Comps Fair Value

$4.43

Comparable-company valuation reference.

Analyst Price Target

$30

Analysts imply upside of 689.5%.

How to read these valuation models

Use the 4 available valuation references for Ernexa Therapeutics Inc (NASDAQ-ERNA) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Ernexa Therapeutics Inc (NASDAQ-ERNA)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

-11.691 M

Current operating profitability reference.

How to read profitability and growth

This section helps investors review Ernexa Therapeutics Inc (NASDAQ-ERNA) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Ernexa Therapeutics Inc (NASDAQ-ERNA)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

4

Mid-range quality score.

Altman Z-Score

-60.9

Lower score that deserves closer risk review.

FCF / Net Income

72.3%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Ernexa Therapeutics Inc (NASDAQ-ERNA). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Ernexa Therapeutics Inc (NASDAQ-ERNA)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 11, 2026

Days to Earnings

50

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Ernexa Therapeutics Inc (NASDAQ-ERNA), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Ernexa Therapeutics Inc (NASDAQ-ERNA) Stock Forecast & Technical Outlook

Review Ernexa Therapeutics Inc (NASDAQ-ERNA) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Ernexa Therapeutics Inc (NASDAQ-ERNA) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Ernexa Therapeutics Inc (NASDAQ-ERNA) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Ernexa Therapeutics Inc (NASDAQ-ERNA) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Ernexa Therapeutics Inc (NASDAQ-ERNA) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Ernexa Therapeutics Inc (NASDAQ-ERNA) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Ernexa Therapeutics Inc (NASDAQ-ERNA)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Ernexa Therapeutics Inc (NASDAQ-ERNA) has a Strong Buy consensus, with 1 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 1
Hold 0
Sell 0
FAQ • Fast Investor Answers

Ernexa Therapeutics Inc (NASDAQ-ERNA) Stock FAQ

Data-supported answers about Ernexa Therapeutics Inc (NASDAQ-ERNA), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$4.43
Estimated upside 16.5%
Valuation Rating
Undervalued
Estimated upside of 16.5%
Analyst Target
$30
Implied upside 689.5%
Financial Health
Weak
Current financial-health read

The current fair value estimate for Ernexa Therapeutics Inc (NASDAQ-ERNA) is $4.43. This implies an estimated upside of 16.5% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 16.5% versus the current market price.

The available analyst price target for Ernexa Therapeutics Inc (NASDAQ-ERNA) is $30. The analyst target implies estimated upside of 689.5%.

The current financial health read for Ernexa Therapeutics Inc (NASDAQ-ERNA) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Ernexa Therapeutics Inc (NASDAQ-ERNA) is November 11, 2026.

The latest available data indicates no current dividend yield for Ernexa Therapeutics Inc (NASDAQ-ERNA).

The current market capitalization listed for Ernexa Therapeutics Inc is 6.203 M.

The current enterprise value listed for Ernexa Therapeutics Inc is 1.525 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Ernexa Therapeutics Inc is NASDAQ-ERNA, and the stock is listed on NASDAQ.

Ernexa Therapeutics Inc (NASDAQ-ERNA) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Ernexa Therapeutics Inc is 5.1%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Ernexa Therapeutics Inc is 73.7%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 468.7 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 221.8 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 189.3 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 130.5 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 80.273 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 72.885 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 61.249 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 56.346 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 41.851 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 41.337 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 33.673 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 33.298 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 27.607 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 26.385 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 25.728 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 25.339 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 21.342 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 20.853 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 15.602 B
NBIX NASDAQ Neurocrine Biosciences Inc Fair Value Undervalued Market Cap 14.46 B